Nitric Oxide-releasing Medications and Colorectal Cancer Risk: The Framingham Study

Background: The major sources of human exposure to nitric oxide (NO) are medicinal nitrovasodilators that release NO into the vasculature. Experimental NO-donating aspirin also releases NO in a similar manner, and is a potent in vitro inhibitor of colon cancer. Materials and Methods: The effects of...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 25; no. 6C; pp. 4471 - 4474
Main Authors MUSCAT, Joshua E, DYER, Anne-Marie, ROSENBAUM, Raphael E, RIGAS, Basil
Format Journal Article
LanguageEnglish
Published Attiki International Institute of Anticancer Research 01.11.2005
Subjects
Aged
Biological and medical sciences
Cohort Studies
Colorectal Neoplasms - chemically induced
Colorectal Neoplasms - epidemiology
Colorectal Neoplasms - prevention & control
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Nitric Oxide Donors - adverse effects
Nitric Oxide Donors - therapeutic use
Pilot Projects
Risk Factors
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Vasodilator Agents - adverse effects
Vasodilator Agents - therapeutic use
Prostaglandin-endoperoxide synthase
Rectal disease
Enzyme
Colorectal cancer
Enzyme inhibitor
Malignant tumor
Acetylsalicylic acid
Epidemiology
Antiplatelet agent
Colonic disease
Cancerology
Nitric oxide
Risk factor
Digestive diseases
Intestinal disease
aspirin
Oxidoreductases
Salicylates
Online AccessGet full text

Cover

More Information
Summary:Background: The major sources of human exposure to nitric oxide (NO) are medicinal nitrovasodilators that release NO into the vasculature. Experimental NO-donating aspirin also releases NO in a similar manner, and is a potent in vitro inhibitor of colon cancer. Materials and Methods: The effects of nitrovasodilators on the risk of colorectal cancer was studied in the Framingham Heart and Offspring studies among 145 cases of colorectal cancer and 433 matched controls. Results: Eleven percent of controls reported currently using nitroglycerine or other long-lasting nitrates. In conditional logistic regression analysis, the odds ratio (OR) for colorectal cancer associated with nitrovasodilator use was 1.2 (95% confidence interval [CI] 0.6, 2.2). In subgroup analysis, the OR was 0.7 (95% CI 0.2, 2.2) in aspirin users and 1.6 (95% CI 0.8, 3.2) in subjects not taking aspirin. Conclusion: These data indicate that NO does not change the risk of colorectal cancer.
ISSN:0250-7005
1791-7530